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Paramagnetic lanthanide chelates for
multicontrast MRI†
Nevenka Cakic´,a Tanja Savic´,a Janice Stricker-Shaver,a Vincent Truﬀault,b
Carlos Platas-Iglesias,c Christian Mirkes,d Rolf Pohmann,d Klaus Scheﬄer*de and
Goran Angelovski*a
The preparation of a paramagnetic chelator that serves as a platform
for multicontrast MRI, and can be utilized either as a T1-weighted,
paraCEST or 19F MRI contrast agent is reported. Its europium(III)
complex exhibits an extremely slow water exchange rate which is
optimal for the use in CEST MRI. The potential of this platform was
demonstrated through a series of MRI studies on tube phantoms and
animals.
Visualization of various biological processes that take place at
cellular and molecular levels is the main goal of modern
diagnostic and molecular imaging techniques. Due to diﬀerent
sensitivity, penetration depth, spatial or temporal resolution
properties of the available imaging methods, the development
of multimodal imaging experienced great advancements in the
last decade.1,2 Nevertheless, a combination of two (or more)
techniques is often challenging, requiring integration of diﬀerent
physical phenomena in the common hardware, or careful design
of multimodal imaging probes.3,4
Today, magnetic resonance imaging (MRI) is one of the most
powerful imaging tools capable of displaying an excellent soft tissue
contrast and furthermore diﬀerent types of contrasts. A number
of diverse MRI contrast agents can improve the specificity of MRI
measurements and, based on their nature, can provide diﬀerent
types of information. The most commonly used 1H-MRI contrast
agents are paramagnetic Gd3+-based complexes or superpara-
magnetic iron-oxide based nanoparticles (T1- and T2-shortening
agents, respectively).5 Recently, an entirely diﬀerent mechanism for
altering an MRI contrast, based on chemical exchange saturation
transfer (CEST), has been developed. Contrast agents for CEST
imaging usually consist of paramagnetic chelates (paraCEST agents)
specifically designed to shift the resonances of exchangeable protons
(NH, OH or bound water) further away from the bulk water.6 One
of the great advantages of CEST is the detectability of its eﬀect in
combination with the presaturation RF pulse; only when this RF
is applied at the specific frequency of the exchangeable protons,
the MRI contrast will appear. Consequently, this method allows
the multi-frequency readout and adjustment of the frequencies
(e.g. by choice of the group with exchangeable protons or choice
of the paramagnetic ion), which can be used for separate
detection and visualization of diﬀerent cellular and tissue environ-
ments.7,8 Finally, MRI can be performed on heteronuclear and
hyperpolarized systems.9 Here, the best choice is 19F NMR because
of its high sensitivity, the easy re-tuning of standard MRI instru-
ments from 1H to 19F nuclei, the high natural abundance of the
19F isotope and the absence of background signals from intrinsic
biomolecules, thus allowing quantitative studies.10,11
With such potential to provide diverse information by employing
diﬀerent frequencies and contrast mechanisms, MRI could be
exploited for concurrent studies by means of T1-weighted, CEST
and 19F imaging protocols. To this aim, it is highly desirable to
develop multicontrast agents, probes capable of making use of these
diﬀerent types of MR contrast, thus resulting in a set of unique
information related to the studied tissue of interest.
We therefore aimed to prepare an agent that is capable of
chelating the paramagnetic ion, possesses frequency-shifted protons
in slow exchange with bulk water, and finally bears a suﬃcient
number of fluorine atoms to provide a sizeable 19F NMR signal
(Fig. 1). We designed ligand L, a derivative of DOTA-tetra-
glycineamide (DOTAM-Gly),12 which displays CEST properties
and ensures good solubility in aqueous solutions, especially after
incorporation of fluorine atoms. The fluorinated moieties were
introduced in the molecule at trans positions of the macrocyclic
ring through two CF3 groups by using a 4-(trifluoromethyl)-L-
phenylalanine (p-CF3-Phe) derivative and a convenient six-step
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synthetic procedure (ESI†). The resulting molecule L underwent
complex formation with the Gd3+, Eu3+ and Tb3+ ions and the
properties of GdL, EuL and TbL were further investigated (ESI†).
Their overall charge should be advantageous (negative) due to
the presence of four carboxylate groups, while appropriate
complex stability necessary for in vivo experiments is ensured
by the kinetic inertness provided by the tetraamide moieties.13
Finally, rigid benzyl moieties may establish, compared to e.g.
aliphatic spacers, a well-defined distance of 19F nuclei from the
paramagnetic center, thus providing advantageous relaxation
properties at the frequency of these nuclei.14
The longitudinal relaxivity of GdL was calculated by obtaining
T1 values of a series of buﬀered solutions at diﬀerent complex
concentrations. The resulting value of 3.1 mM1 s1 is expected for
monohydrated tetraamide complexes with a slow water exchange
rate.15 CEST measurements were performed by selective presatura-
tion of the EuL and TbL samples in incremental steps over a range
of frequencies followed by plotting the remaining steady-state bulk
water signal, Mz/M0, as a function of saturation frequency (Fig. 2).
The resulting Z-spectra of EuL exhibited a strong CEST eﬀect
(B50% at 25 1C, 15 mM, B1 = 25.0 mT) centred at 50 ppm relative
to bulk water, which is commonly associated with the water
molecule directly coordinated to Eu3+. The CEST eﬀect remains
strong at 37 1C along with slight broadening and shifting of the
CEST signal (5 ppm) towards the bulk water resonance due to the
hyperfine shift eﬀect of Eu3+ (Fig. 2, top).16
Water exchange rates at both temperatures were determined
using a concentration-independent method previously developed by
Sherry and colleagues,16 and were confirmed by quantification of
the exchange rates as a function of saturation time or saturation
power (QUEST and QUESP experiments, respectively).17 The values
obtained from these experiments revealed extremely slow exchange
rates of around 1 and 2 kHz or bound-water lifetimes (tM) of
around 1 ms and 500 ms at 25 and 37 1C, respectively (Table 1).
These residence times are as long as those reported very
recently for the phosphonate esters of DOTAM-Gly at 25 1C,18
likely due to the presence of hydrophobic p-CF3-Phe moieties.
Consequently, EuL displays an almost optimal tM which lies in
the range of 104–102 s, allowing CEST experiments using
weaker B1 fields. On the other hand, TbL displayed a weak CEST
effect for both the inner-sphere water molecule and amide
protons (ESI†), probably for the same reasons related to slow
water exchange as in EuL.19,20
19F NMR spectra of GdL, EuL and TbL were recorded and
19F relaxation rates were determined to estimate the potential
of these agents for 19F MRI. GdL displayed a single broad 19F NMR
resonance, indicating substantial shortening of the relaxation
times, while EuL and TbL revealed the existence of at least three
paramagnetic species in the solution with diﬀerent 19F chemical
shifts (ESI†). While the two peaks with higher intensities can be
assigned to the common monocapped square-antiprismatic and
monocapped twisted square-antiprismatic (SAP and TSAP,
respectively) isomers of this type of compound,21 the appearance
of the third resonance with very weak intensity can be explained
by racemization of the starting amino acid or racemization of
alkylating arms prior to or during alkylation of cyclen, as
previously observed for similar systems under comparable
experimental conditions.22 Consequently, 19F relaxation rates
were determined only for the most abundant peaks (Table 2).
Fig. 1 The chemical structure of chelator L described in this work:
paramagnetic ion makes it suitable for T1-weighted or paraCEST MRI,
while nearby CF3 groups enable
19F NMR, concurrently taking advantage of
the paramagnetic enhancement eﬀect.
Fig. 2 CEST experiments with EuL (15 mM). (top) Z-spectra of EuL at
B1 = 25.0 mT and irradiation time = 5 s; (bottom) determination of water
exchange rates at 25 1C (blue) and 37 1C (red) at B1 = 35.0, 30.0, 25.0, 22.5,
20.0, 17.5, 15.0 and 10.0 mT, and irradiation time = 10 s.
Table 1 Water exchange rates (in Hz) obtained for EuL using the two
independent methods
Temperature Omega plots QUEST/QUESP
25 1C 1176  22 930  11
37 1C 2036  110 2000  138
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As expected, GdL dramatically aﬀected both 19F R1 and R2, while
still keeping a favorable R1/R2 ratio to obtain a good signal-to-
noise ratio (SNR), when using ultrafast sequences.23 EuL and
TbL also enhanced 19F R1 and R2, however the reduction in the
R1/R2 ratio (in the case of EuL) or larger signal splitting (in the
case of TbL) suggests GdL as a better candidate for 19F MRI
studies, with the current DOTA-type chelator.
The potential of these systems to serve as multicontrast
agents was demonstrated using in vitro MRI on tube phantoms
(Fig. 3a–d). Four tubes containing GdL, EuL, TbL and water as
controls were imaged using a 7T MRI scanner by different
imaging protocols and frequencies. The greatest effect on relaxation
times and hence the signal enhancement in T1-weighted MRI
experiments was observed for GdL (Fig. 3a), as would be expected;
this effect was also confirmed by T2-weighted MRI experiments
(Fig. 3b). All three complexes displayed very good 19F MRI contrasts
using the sequence parameters adjusted to assume different
19F relaxation rates due to influence of different paramagnetic
ions (Fig. 3c). Lastly, only EuL exhibited a strong contrast in the
CEST MRI experiment (Fig. 3d), as already indicated above in
the NMR CEST experiments.
To confirm this platform as a multicontrast MRI agent in a
complex environment, we have carried out an MRI study on
animals using GdL and EuL. The contrast agent was injected
intracranially into the somatosensory cortex of the anesthetized
rats outside the scanner. For GdL, the animal was transferred
into the scanner, and a very strong T1-weighted MRI signal was
recorded in vivo (Fig. 3e). Slow reduction in the MRI signal over
a period of a few hours indicated very slow diﬀusion of GdL and
its potential interaction with brain tissues. Although a similar
behavior was previously observed with aminobisphosphonate-
containing contrast agents,24 it is hard to rationalize this eﬀect
with the current chelating platform since its diﬀusion properties
in solution did not indicate any aggregation, i.e. the diﬀusion
coeﬃcient corresponded to other monomeric agents of similar
size (ESI†).
Additionally, the eﬀect of EuL was assessed by means of MRI
ex vivo. A weak T1-weigthed MRI contrast was obtained as
expected after the animal was euthanized and transferred into
the scanner (Fig. 3f). In parallel, a strong CEST contrast (B10%
signal change) was successfully obtained at the frequency of the
inner-sphere water molecule bound to Eu3+ (Fig. 3g), confirming
the great potential of EuL for further paraCEST studies due to its
long tM (vide supra). In regard to
19F MRI, several imaging
sequences were tested on both GdL and EuL, using non-fluorine
containing anesthesia to avoid possible interferences at the fluorine
frequency. However, only a slight change in signal intensity could
be detected after 2.3 hours of monitoring. As already discussed
above, the lack of signals could indicate an interaction of the agent
with surrounding tissues, which significantly reduces 19F T2 relaxa-
tion times and leads to signal disappearance (a notable broadening
of the 19F signal in the measured 1D spectrum was observed for
GdL). However, this eﬀect can likely be avoided with another
experimental design where the tissue density is lower (e.g. in the
blood stream or kidneys), or by combining this platform to a
nanosized system that will prevent any interaction with the tissue
and improve the agent’s biocompatibility.25
In conclusion, we report a promising platform for the develop-
ment of multicontrast agents for MRI. A small size molecule
accommodates diﬀerent paramagnetic ions and subsequently
enhances 1H T1-weighted,
1H CEST, and 19F MRI contrasts. The
GdL and EuL complexes can concurrently serve as 1H T1-weighted
and 19F MRI, or as 1H CEST and 19F MRI agents, respectively. As
these two complexes are expected to have essentially the same
biodistribution, the three diﬀerent contrast mechanisms could be
exploited using the same molecular platform, even if GdL and EuL
have to be administered separately.26 Furthermore, the installa-
tion of the aromatic fluorinated units likely caused extremely
advantageous exchange rates in EuL for CEST experiments,20
Table 2 19F relaxation rates of GdL, EuL and TbL (300 MHz, 25 1C)
Temperature 19F R1 (Hz)
19F R2 (Hz)
GdL 182 385
EuL 1.4a,b 18
a
19b
TbL
32a 48a
12b 28b
a More abundant isomer. b Less abundant isomer.
Fig. 3 MRI experiments with the multicontrast agent. In vitro MRI on tube
phantoms with 5 mM of complexes (pH 7.3, HEPES, 25 1C): (a) T1-weighted
MRI; (b) T2-weighted MRI; (c)
19F MRI; (d) paraCEST MRI. In vivo (GdL) and
ex vivo (EuL) MRI in rat cortex: (e) T1-weighted MRI withGdL; (f) T1-weighted
MRI with EuL; (g) merged CEST and T1-weighted MRI with EuL. Arrows
indicate the region where the contrast agent was injected; bars show signal
intensity in arbitrary units except %CEST in (g).
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while possibly deteriorating the agent’s biocompatibility for
19F MRI. Nevertheless, further improvements should easily be
envisaged to provide the optimized multicontrast agent. Structural
optimizations towards adjustment of the chelator’s coordination
properties may lead to a single isomer species that will be beneficial
for 19F MRI. Synthetic modifications can lead to a higher number of
fluorine atoms per molecule to increase the signal intensity, while a
combination with various nanocarriers can improve the delivery,
biokinetics and potentiality also the T2 contrast of this multicontrast
agent. The ability to collect diﬀerent types of information from a
single imaging probe just by using diﬀerent imaging protocols
brings new quality to MRI and can be a great asset for current
molecular imaging to study various biological phenomena.
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